These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26346796)

  • 41. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Multiple sclerosis: a degenerative disease?].
    Confavreux C; Vukusic S
    Bull Acad Natl Med; 2008 Mar; 192(3):483-91; discussion 492-3. PubMed ID: 18819694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current and future role of interferon beta in the therapy of multiple sclerosis.
    Farrell RA; Giovannoni G
    J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Black holes in multiple sclerosis: definition, evolution, and clinical correlations.
    Sahraian MA; Radue EW; Haller S; Kappos L
    Acta Neurol Scand; 2010 Jul; 122(1):1-8. PubMed ID: 20003089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The importance of early diagnosis of multiple sclerosis.
    Miller JR
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S4-11. PubMed ID: 15253684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brain health: time matters in multiple sclerosis.
    Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
    Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.
    Francis GS
    J Neurol; 2004 Sep; 251 Suppl 5():v42-v49. PubMed ID: 15549355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
    Zivadinov R; Reder AT; Filippi M; Minagar A; Stüve O; Lassmann H; Racke MK; Dwyer MG; Frohman EM; Khan O
    Neurology; 2008 Jul; 71(2):136-44. PubMed ID: 18606968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview of treatment options in multiple sclerosis.
    Waubant E
    J Clin Psychiatry; 2012 Jun; 73(6):e22. PubMed ID: 22795209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.
    Rotstein D; Montalban X
    Nat Rev Neurol; 2019 May; 15(5):287-300. PubMed ID: 30940920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching algorithms: from one immunomodulatory agent to another.
    Coyle PK
    J Neurol; 2008 Mar; 255 Suppl 1():44-50. PubMed ID: 18317676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment optimization in multiple sclerosis: report of an international consensus meeting.
    International Working Group for Treatment Optimization in MS
    Eur J Neurol; 2004 Jan; 11(1):43-7. PubMed ID: 14692887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    Singer BA; Feng J; Chiong-Rivero H
    J Neurol; 2024 Jun; 271(6):3116-3130. PubMed ID: 38615277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lessons from immunotherapies in multiple sclerosis.
    Rispoli MG; D'Apolito M; Pozzilli V; Tomassini V
    Handb Clin Neurol; 2023; 193():293-311. PubMed ID: 36803817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Hartung HP; Meuth SG; Thompson AJ
    Mult Scler; 2021 Sep; 27(10):1473-1476. PubMed ID: 34472985
    [No Abstract]   [Full Text] [Related]  

  • 59. Optimizing treatment success in multiple sclerosis.
    Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
    J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Tramacere I; Del Giovane C; Salanti G; D'Amico R; Filippini G
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011381. PubMed ID: 26384035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.